Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 1—January 2004
Research

Respiratory and Urinary Tract Infections, Arthritis, and Asthma Associated with HTLV-I and HTLV-II Infection

Edward L. Murphy*, Baoguang Wang†, Ronald A. Sacher‡, Joy Fridey§, James W. Smith¶, Catharie C. Nass#, Bruce Newman**, Helen E. Ownby**, George Garratty††, Sheila T. Hutching††, and George B. Schreiber†
Author affiliations: *University of California San Francisco, California, USA; †Westat, Rockville, Maryland, USA; ‡Hoxworth Blood Center, Cincinnati, Ohio, USA; §Blood Bank of San Bernardino and Riverside Counties, San Bernardino, California, USA; ¶Oklahoma Blood Institute, Oklahoma City, Oklahoma, USA; #American Red Cross Blood Services Chesapeake and Potomac, Baltimore, Maryland, USA; **American Red Cross Blood Services Southeastern Michigan, Detroit, Michigan, USA; ††American Red Cross Blood Services Southern California, Los Angeles, California, USA

Main Article

Table 4

Prevalence of medically diagnosed symptoms, and unadjusted and adjusted odds ratios (OR) derived from logistic regression models, in human T-lymphotropic virus (HTLV)-I– and HTLV-II–infected participants and HTLV-seronegative participants, visits 2 and 3a

Symptoms HTLV seronegative 
(N = 799) HTLV-I (N = 152) HTLV-II (N = 387)
Cases (%)b Cases (%)b ORc Adj. OR (95% CI)d Cases (%)b ORc Adj. OR (95% CI)d
Trouble walking, climbing or rising from chair 147 (21) 52 (42) 2.71 2.67 (1.74 to 4.09) 133 (42) 2.78 3.44 (2.52 to 4.71)
Incontinence, pre- or post-void urgency 175 (25) 50 (40) 2.03 2.02 (1.33 to 33.07) 134 (43) 2.25 2.59 (1.92 to 3.49)
Lymphadenopathy 29 (4) 11 (9) 2.26 2.39 (1.14 to 5.03) 40 (13) 3.40 3.08 (1.85 to 5.13)
Night sweats 20 (3) 15 (12) 4.68 4.73 (2.31 to 9.69) 47 (15) 6.02 4.97 (2.77 to 8.94
Weight loss 40 (6) 9 (7) 1.29 1.10 (0.51 to 2.37) 40 (13) 2.43 2.10 (1.22 to 3.60)
Foot paresthesias 57 (8) 22 (18) 2.44 2.46 (1.41 to 4.28 66 (21) 3.02 3.27 (2.19 to 4.88)
Impotence (males only) 33 (5) 10 (8) 2.24 2.05 (0.77 to 5.49) 13 (4) 1.10 1.27 (0.56 to 2.91)

aOnly the first diagnosis of each symptom is considered for each participant.
bDenominator for percentage calculation varied according to the number of participants included in each disease-specific analysis.
cUnadjusted.
dAdjusted. Models were adjusted for age, race and ethnicity, and duration of follow-up (all symptoms), and gender (all except impotence). In addition, specific models included community versus autologous donation (for trouble walking and incontinence, weight loss and impotence.) and injection drug use [night sweats and weight loss]).

Main Article

Page created: December 21, 2010
Page updated: December 21, 2010
Page reviewed: December 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external